Novartis India Ltd (NOVARTIND) is currently trading at 1,715.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Novartis India Limited (NIL) is a pharmaceutical manufacturer and marketer in India operating legacy Novartis and Sandoz brands across Pharmaceuticals, Generics, Over‑the‑Counter and Animal Health segments, now refocused under new majority ownership by ChrysCapital to revive and grow established prescription and consumer healthcare franchises. Following a July 2026 promoter change to ChrysCapital (70.68% stake), NIL has installed a new management team and board and signaled a strategic commercial reset focused on six anchor therapy areas, aiming to convert deep prescriber equity in brands such as Voveran and Tegrital into accelerated growth. Management targets a run‑rate near INR650 crore for FY27 and has publicly stated an aspiration to double revenues in four to five years, while acknowledging near‑term margin compression from upfront hiring, distribution expansion and one‑time transition costs. NIL has already completed material transactions: trademark acquisition of Minipress XL from Pfizer and in‑licensing of ophthalmology injectables Pagenax and Accentrix, using brand purchases and in‑licensing as the primary route to broaden its specialty and chronic therapy presence. The strategy emphasises disciplined capital deployment, avoidant stance on new manufacturing capex at current scale, lifecycle management of legacy brands, and prioritising bolt‑on M&A and promotional investment to deliver ROCE and free cash flow improvements over the medium term.

Over the past 52 weeks, Novartis India Ltd has traded between a low of ₹750.00 and a high of ₹2,588.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Novartis India Ltd has a market capitalization of approximately 4,477.18. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Novartis India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 45.79 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 4,477.18 Cr, Novartis India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Novartis India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Novartis India Ltd is 45.79. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The Board meeting is scheduled for October 8, 2026.

Novartis India informed BSE that the board will meet on November 3, 2026, to consider and approve unaudited results for the quarter and half-year ended September 30, 2026.

Novartis India acquired the ‘Minipress’ and ‘Minipres’ trademarks from Pfizer in India.

The stock rose about 18% to 20% after Novartis AG announced it will sell its 70.68% stake to a ChrysCapital-led consortium, triggering a mandatory open offer.